Company news

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) news

Sangamo Therapeutics, Inc. news releases on 6ix. Latest, Jun 8, 2026: Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value…

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) news

Press releases & updates

Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results

Sangamo Therapeutics Announces First Quarter 2026 Earnings Call

Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)

Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market

Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call

Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026

Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering

Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results

Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec

Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results

Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast

Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results

Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases

Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast

Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing

Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast

Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast

Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile